Modality
Vaccine
MOA
BCL-2i
Target
CGRP
Pathway
RAS/MAPK
Atopic Derm
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
~Jun 2018
→ ~Sep 2019
Phase 3
~Dec 2019
→ ~Mar 2021
NDA/BLA
Jun 2021
→ Dec 2030
NDA/BLACurrent
NCT04563785
858 pts·Atopic Derm
2021-06→2030-12·Recruiting
858 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-214.7y awayPh3 Readout· Atopic Derm
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2030-12-21 · 4.7y away
Atopic Derm
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04563785 | NDA/BLA | Atopic Derm | Recruiting | 858 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |